CAPLYTA®: Clinical Indications and Practical Application in Advanced Practice

Please join us for an educational speaker dinner focused on CAPLYTA® (lumateperone), an FDA-approved prescription medication for adults indicated for the treatment of schizophrenia, bipolar I or II depression (as monotherapy or as adjunctive therapy with lithium or valproate), and as add-on therapy for major depressive disorder (MDD).

This program will provide an overview of the current evidence base supporting lumateperone, including approved indications, mechanism of action, efficacy data, safety profile, and practical considerations for patient selection. Participants will also review real-world clinical considerations such as dosing, tolerability, and integration into treatment plans. CAPLYTA® is administered as a once-daily oral capsule and does not require dose titration, which may influence adherence and implementation in clinical practice.

This session is designed for advanced practice nurses and other prescribing clinicians seeking to remain current on emerging and evolving pharmacologic treatment options in serious mental illness. The evening will include a sponsored dinner and opportunity for collegial discussion.